Our experts reflect on the trends that shaped the European pricing and market access landscape in 20...
Read moreWe summarise the ISPOR Europe 2022 conference including plenary sessions on HTA, patient-centered re...
Read moreOur experts provide a detailed summary of Plenary Session 2 at ISPOR 2022 on innovative methods for ...
Read moreOur experts provide a detailed summary of Plenary Session 1 at ISPOR 2022 on the Convergence of HTA ...
Read moreWe summarise four handpicked articles from pharmaceutical, pricing and market access that are worth ...
Read moreEUCOPE and EFPIA have issued a joint statement expressing concerns regarding the implementation of t...
Read moreA cross-border alliance of health technology assessment (HTA) agencies has been announced by the Can...
Read moreWe summarise four handpicked articles from pharmaceutical, pricing and market access that are worth ...
Read moreThe short answer to the question “how important is HTA when launching a biosimilar in the EU5?” ...
Read moreWe investigate Single Technology Appraisals (STAs) conducted by NICE, comparing outcomes for monothe...
Read more